• Je něco špatně v tomto záznamu ?

Clinical relevance of uPA, uPAR, PAI 1 and PAI 2 tissue expression and plasma PAI 1 level in colorectal carcinoma patients

J. Halamkova, I. Kiss, Z. Pavlovsky, J. Jarkovsky, J. Tomasek, S. Tucek, L. Hanakova, M. Moulis, Z. Cech, J. Zavrelova, M. Penka

. 2011 ; 58 (112) : 1918-1825.

Jazyk angličtina Země Řecko

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc12022298

BACKGROUND/AIMS: Urokinase (uPA) is a serine protease, which together with uPAR, tPA, PAI 1 and PAI 2 forms the plasminogen activator system, a component of metastatic cascade contributing to the invasive growth and angiogenesis of malignant tumours. METHODOLOGY: Both preceding therapy and after 6-8 weeks of the treatment, plasma PAI 1 levels (photometric microplate method on the ELISA) and uPA, uPAR, PAI 1 and PAI 2 tissue expression (immunohistochemical reaction) were analysed from 80 colorectal carcinoma patients. RESULTS: Analysis showed higher pre-treatment plasma levels of PAI 1 in patients with advanced tumours, which decreased after surgery or the start of therapy (p=0.004); Patients with higher plasma level PAI 1 before (0.013) and after therapy (0.004) had significantly shorter survival. There was a higher expression of uPA (p<0.001), uPAR (p<0.001), PAI 1 (p=0.042) and PAI 2 (p<0.001) in advanced colorectal carcinoma. A relationship between PAI 2 (p=0.010) and uPAR (p=0.019) expression and survival was demonstrated. There is a correlation between pre-treatment plasma PAI 1 levels and PAI 2 (p=0.028) and uPAR (p=0.043) expression. CONCLUSIONS: Immunohistochemical analysis of PAS in tumour tissue and plasma PAI 1 levels was found to be a useful prognostic factor in colorectal carcinoma patients. Plasma PAI 1 could be advantageous in evaluating the effectiveness of a mode of treatment.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc12022298
003      
CZ-PrNML
005      
20160405111557.0
007      
ta
008      
120806s2011 gr f 000 0#eng||
009      
AR
024    7_
$a 10.5754/hge10232 $2 doi
035    __
$a (PubMed)22234062
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a gr
100    1_
$a Halámková, Jana $7 xx0121826 $u Masaryk Memorial Cancer Institute, Masaryk University, Brno, Czech Republic. jana.halamkova@mou.cz
245    10
$a Clinical relevance of uPA, uPAR, PAI 1 and PAI 2 tissue expression and plasma PAI 1 level in colorectal carcinoma patients / $c J. Halamkova, I. Kiss, Z. Pavlovsky, J. Jarkovsky, J. Tomasek, S. Tucek, L. Hanakova, M. Moulis, Z. Cech, J. Zavrelova, M. Penka
520    9_
$a BACKGROUND/AIMS: Urokinase (uPA) is a serine protease, which together with uPAR, tPA, PAI 1 and PAI 2 forms the plasminogen activator system, a component of metastatic cascade contributing to the invasive growth and angiogenesis of malignant tumours. METHODOLOGY: Both preceding therapy and after 6-8 weeks of the treatment, plasma PAI 1 levels (photometric microplate method on the ELISA) and uPA, uPAR, PAI 1 and PAI 2 tissue expression (immunohistochemical reaction) were analysed from 80 colorectal carcinoma patients. RESULTS: Analysis showed higher pre-treatment plasma levels of PAI 1 in patients with advanced tumours, which decreased after surgery or the start of therapy (p=0.004); Patients with higher plasma level PAI 1 before (0.013) and after therapy (0.004) had significantly shorter survival. There was a higher expression of uPA (p<0.001), uPAR (p<0.001), PAI 1 (p=0.042) and PAI 2 (p<0.001) in advanced colorectal carcinoma. A relationship between PAI 2 (p=0.010) and uPAR (p=0.019) expression and survival was demonstrated. There is a correlation between pre-treatment plasma PAI 1 levels and PAI 2 (p=0.028) and uPAR (p=0.043) expression. CONCLUSIONS: Immunohistochemical analysis of PAS in tumour tissue and plasma PAI 1 levels was found to be a useful prognostic factor in colorectal carcinoma patients. Plasma PAI 1 could be advantageous in evaluating the effectiveness of a mode of treatment.
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a kolorektální nádory $x metabolismus $x mortalita $7 D015179
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a imunohistochemie $7 D007150
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a inhibitor aktivátoru plazminogenu 1 $x analýza $x krev $7 D017395
650    _2
$a inhibitor aktivátoru plazminogenu 2 $x analýza $7 D017396
650    _2
$a receptory urokinázového aktivátoru plazminogenu $x analýza $7 D055293
650    _2
$a aktivátor plasminogenu urokinasového typu $x analýza $7 D014568
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Kiss, Igor, $d 1965- $7 xx0031864
700    1_
$a Pavlovský, Zdeněk, $d 1971- $7 xx0136659
700    1_
$a Jarkovský, Jiří $7 stk2008461294
700    1_
$a Tomášek, Jiří $7 xx0107945
700    1_
$a Tuček, Štěpán $7 xx0227528
700    1_
$a Hanáková, Lada. $7 xx0275403
700    1_
$a Moulis, Mojmír $7 xx0121681
700    1_
$a Čech, Zbyněk $7 xx0126345
700    1_
$a Zavřelová, Jiřina $7 xx0168330
700    1_
$a Penka, Miroslav, $d 1952- $7 nlk19990073680
773    0_
$w MED00002025 $t Hepato-gastroenterology $x 0172-6390 $g Roč. 58, č. 112 (2011), s. 1918-1825
856    41
$u https://pubmed.ncbi.nlm.nih.gov/22234062 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y m $z 0
990    __
$a 20120806 $b ABA008
991    __
$a 20160405111633 $b ABA008
999    __
$a ok $b bmc $g 944211 $s 779595
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2011 $b 58 $c 112 $d 1918-1825 $i 0172-6390 $m Hepato-gastroenterology $n Hepatogastroenterology $x MED00002025
LZP    __
$b NLK111 $a Pubmed-20120806/12/01

Najít záznam

Citační ukazatele

    Možnosti archivace